Invention Grant
- Patent Title: Medical intervention in haematological cancers
- Patent Title (中): 医学干预血液肿瘤
-
Application No.: US12994491Application Date: 2009-05-26
-
Publication No.: US08501734B2Publication Date: 2013-08-06
- Inventor: Lukas Huber , Simon Schnaiter , Inge Tinhofer , Karin Jöhrer , Richard Greil
- Applicant: Lukas Huber , Simon Schnaiter , Inge Tinhofer , Karin Jöhrer , Richard Greil
- Applicant Address: AT Innsbruck
- Assignee: Oncotyrol-Center for Personalized Cancer Medicine GmbH (Ltd.)
- Current Assignee: Oncotyrol-Center for Personalized Cancer Medicine GmbH (Ltd.)
- Current Assignee Address: AT Innsbruck
- Agency: Foley & Lardner LLP
- Priority: EP08009559 20080526
- International Application: PCT/EP2009/003736 WO 20090526
- International Announcement: WO2009/144009 WO 20091203
- Main IPC: A61K31/535
- IPC: A61K31/535
Abstract:
The present invention relates to the medical and pharmaceutical use of substituted 1H-imidazo[4,5-c]quinolin-4-amines, in particular Imiquimod® and Gardiquimod®, alone or preferably in combination with Akt inhibitors, in particular with Akti1/2 and AktX, and most preferably with Akti1/2, in the treatment, prevention and/or amelioration of haematological cancers, in particular multiple myeloma disorders or B-cell disorders, and most particular in the therapy of multiple myeloma.
Public/Granted literature
- US20110178076A1 MEDICAL INTERVENTION IN HAEMATOLOGICAL CANCERS Public/Granted day:2011-07-21
Information query
